Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sonova Holding AGXSWX:SOON -0.87%89 EV-to-EBITDA is 14.20 as of Jul. 20, 2026, which is 25% below its 10-year median of 18.95. GuruFocus rates XSWX:SOON with a GF Score™ of 89/100 and a GF Value™ of CHF250.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Sonova Holding AG ranks worse than 50.59% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sonova Holding AG's enterprise value is CHF13,213 Mil.
Sonova Holding AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF931 Mil. Therefore, Sonova Holding AG's EV-to-EBITDA for today is 14.20.
The historical rank and industry rank for Sonova Holding AG's EV-to-EBITDA or its related term are showing as below:
XSWX:SOON'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.05 Med: 18.95 Max: 29.94
Current: 14.2
During the past 13 years, the highest EV-to-EBITDA of Sonova Holding AG was 29.94. The lowest was 12.05. And the median was 18.95.
XSWX:SOON's EV-to-EBITDA is ranked worse than 50.59% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs XSWX:SOON: 14.20
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Sonova Holding AG (XSWX:SOON) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sonova Holding AG's PE Ratio (TTM) for today is calculated as:
Sonova Holding AG's share price for today is CHF205.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sonova Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was CHF7.220.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sonova Holding AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SOON vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Sonova Holding AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonova Holding AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sonova Holding AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sonova Holding AG's EV-to-EBITDA falls into.
Sonova Holding AG's current Enterprise Value is CHF13,213 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sonova Holding AG's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was CHF931 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonova Holding AG (XSWX:SOON) has a EV-to-EBITDA of 14.20 as of Jul. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sonova Holding AG. This is 25% below median its historical median of 18.95. Over the past decade, Sonova Holding AG's EV-to-EBITDA has ranged from 12.05 to 29.94. According to the industry distribution chart, Sonova Holding AG ranks #258 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 50.6%.
Is Sonova Holding AG's EV-to-EBITDA too high?
Sonova Holding AG's current EV-to-EBITDA of 14.20 is 25% below median its 10-year median of 18.95. Over the past 10 years, this metric has ranged from a low of 12.05 to a high of 29.94. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.16. Sonova Holding AG's value of 14.20 is 0.3% above this industry median. Based on the distribution chart, Sonova Holding AG ranks #258 out of 510 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sonova Holding AG has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonova Holding AG's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sonova Holding AG ranks #258 out of 510 companies for EV-to-EBITDA. This places Sonova Holding AG in the lower half of its industry. The industry median EV-to-EBITDA is 14.16. Sonova Holding AG's value of 14.20 is 0.3% above this benchmark. Historically, Sonova Holding AG's own EV-to-EBITDA has ranged from 12.05 to 29.94 over the past decade. While the company's 10-year median is 18.95 vs. the industry median of 14.16, Sonova Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sonova Holding AG's current EV-to-EBITDA of 14.20 is 0.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sonova Holding AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonova Holding AG's current EV-to-EBITDA is 14.20, which is 25% below median its own 10-year median of 18.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonova Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Sonova Holding AG (XSWX:SOON) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF250.61, compared to a current price of CHF205.40 — trading 18% below its estimated fair value. The current EV-to-EBITDA is 14.20, which is 25% below median its 10-year median of 18.95 and 0.3% above the Medical Devices & Instruments industry median of 14.16. Sonova Holding AG's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sonova Holding AG (XSWX:SOON), the current EV-to-EBITDA is 14.20 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonova Holding AG (XSWX:SOON) Overvalued in 2026?
Based on GuruFocus' analysis, Sonova Holding AG stock appears to be undervalued.
The current stock price of CHF205.40 is trading 18% below its estimated GF Value™ of CHF250.61.
GuruFocus considers Sonova Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:SOON:
EV-to-EBITDA: 14.20 (25% below median its 10-year median of 18.95)
GF Value™: CHF250.61 vs. price of CHF205.40 (18% below fair value)
Industry Position: 0.3% above the Medical Devices & Instruments median (#258 of 510)
No single metric tells the full story. See the XSWX:SOON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonova is one of the world's largest manufacturers and distributors of hearing aids. The company is based in Switzerland and distributes its products in more than 100 countries through its internal sales team and independent retailers. It also sells cochlear implants and audio technologies.
89GF Score
Get the complete analysis for XSWX:SOON
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SOON has been successfully added to your 
